Safety of testosterone use in women

被引:42
作者
Shufelt, Chrisandra L. [1 ]
Braunstein, Glenn D. [1 ]
机构
[1] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA
关键词
Testosterone; Androgens; Safety; Breast cancer; Endometrial cancer; Cardiovascular system; SURGICALLY MENOPAUSAL WOMEN; ENDOGENOUS SEX-HORMONES; BREAST-CANCER RISK; POSTMENOPAUSAL WOMEN; REPLACEMENT THERAPY; ESTROGEN-ANDROGEN; DOUBLE-BLIND; PROLIFERATION; PROGESTERONE; METABOLISM;
D O I
10.1016/j.maturitas.2009.01.012
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Female sexual desire appears to be in part androgen dependent, which has lead to the use of testosterone in women for low libido. Despite this benefit, the long-term safety of testosterone as a hormone replacement or therapy has not been well established. Side effects of testosterone therapy include mild and reversible acne and hirsuitism, as well as changes to the lipid profile with oral, but not transdermal testosterone. Short-term studies, up to 2 years, have shown that for serum plasma testosterone levels at the upper portion or slightly above the reference range for reproductive-aged women, testosterone does not increase the risk of hepatotoxicity, endometrial hyperplasia, or behavioral hostility. No adverse cardiovascular effects including changes in blood pressure, blood viscosity, arterial vascular reactivity, hypercoagulable states, and polycythemia have been shown. Data is mixed with outcomes of breast cancer risk, with some experimental studies suggesting a decrease in estrogen-induced breast epithelial proliferation with low close testosterone. Additionally, models of superphysiologic testosterone levels, such as polycystic ovarian disease, have not shown an increased risk of breast cancer. As with all hormone therapy in postmenopausal women, testosterone therapy should be individualized and requires that each woman weigh the risk and benefits. Nevertheless, only long-term safety studies will provide conclusive evidence as to testosterone safety in women. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:63 / 66
页数:4
相关论文
共 47 条
[1]  
Anderson KE, 1997, CANCER, V79, P494, DOI 10.1002/(SICI)1097-0142(19970201)79:3<494::AID-CNCR10>3.3.CO
[2]  
2-#
[3]  
[Anonymous], 2001, J PSYCHOL HUM SEX, V13, P1, DOI DOI 10.1300/J056V13N01_01
[4]  
BARLOW DH, 1986, OBSTET GYNECOL, V67, P321
[5]  
Barrett-Connor E, 1999, J REPROD MED, V44, P1012
[6]   PROSPECTIVE-STUDY OF ENDOGENOUS SEX-HORMONES AND FATAL CARDIOVASCULAR-DISEASE IN POSTMENOPAUSAL WOMEN [J].
BARRETTCONNOR, E ;
GOODMANGRUEN, D .
BRITISH MEDICAL JOURNAL, 1995, 311 (7014) :1193-1196
[7]   Safety and adverse effects of androgens: How to counsel patients [J].
Basaria, S ;
Dobs, AS .
MAYO CLINIC PROCEEDINGS, 2004, 79 (04) :S25-S32
[8]   Effect of methyl testosterone administration on plasma viscosity in postmenopausal women [J].
Basaria, S ;
Nguyen, T ;
Rosenson, RS ;
Dobs, AS .
CLINICAL ENDOCRINOLOGY, 2002, 57 (02) :209-214
[9]   Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP Breast Cancer Prevention Trial (P-1) [J].
Beattie, MS ;
Costantino, JP ;
Cummings, SR ;
Wickerham, DL ;
Vogel, VG ;
Dowsett, M ;
Folkerd, EJ ;
Willett, WC ;
Wolmark, N ;
Hankinson, SE .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (02) :110-115
[10]   Serum sex hormone levels after menopause and subsequent breast cancer [J].
Berrino, F ;
Muti, P ;
Micheli, A ;
Bolelli, G ;
Krogh, V ;
Sciajno, R ;
Pisani, P ;
Panico, S ;
Secreto, G .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (05) :291-296